ANTIMIKROBNA OSETLJIVOST BAKTERIJA RODA ACINETOBAKTER IZOLOVANIH IZ INFICIRANIH RANA U TERCIJARNOJ ZDRAVSTVENOJ USTANOVI

Ivana Dragoslav Rosić; Nikola Vojislav Rosić; Slobodan Mirko Simović

doi:10.5937/racter5-3323

Ivana Dragoslav Rosić Univerzitet u Kragujevcu, Medicinski fakultet
Nikola Vojislav Rosić Univerzitet u Kragujevcu, Medicinski fakultet
Slobodan Mirko Simović Univerzitet u Kragujevcu, Medicinski fakultet

DOI: https://doi.org/10.5937/racter5-3323

Ključne reči: Antibiotics||, ||Antibiotici, Wound Infection||, ||Infekcija rane, Resistance||, ||Rezistencija, Acinetobacter||, ||Acinetobakter,

Sažetak

Bakterije roda Acinetobakter, a posebno vrsta Acinetobacter baumanii, su jedan od najznačajnijih uzročnika infekcije kod imunokompromitovanih pacijenata u bolničkim uslovima.

Cilj istraživanja je bio da se utvrdi na koje antibiotike bakterije roda Acinetobakter, izolovane u brisevima inficiranih rana pacijenata Kliničkog centra Kragujevac pokazuju najveću osetljivost, kao i da se ustanovi da li postoji razlika između in vitro osetljivosti u jedinicama intenzivnog lečenja i drugim, hirurškim i internističkim, odeljenjima.

Retrospektivno je analizirano 220 briseva rana pacijenata Kliničkog centra tokom 2011. godine, u kojima je izolovana samo bakterija roda Acinetobakter, i praćena je njena osetljivost na karakterističnu paletu antibiotika.

Najveću efikasnost in vitro protiv izolata acinetobaktera u svim analiziranim organizacionim jedinicama Kliničkog centra su pokazali ampicilin sa sulbaktamom, kolistin i tigeciklin. Lekovi na koje su samo poneki izolati Acinetobaktera osetljivi su ko-trimoksazol, amikacin, imipenem i meropenem.

Acinetobakter pokazuje najveću osetljivost in vitro na ampicilin sa sulbaktamom, kolistin i tigeciklin. Osetljivost izolata Acinetobaktera na antibiotike je manje izražena u jedinicama intenzivnog lečenja u odnosu na druga odeljenja.

Biografije autora

Ivana Dragoslav Rosić, Univerzitet u Kragujevcu, Medicinski fakultet

Lekar, Centar za onkologiju, Odeljenje za radioterapiju, Klinički centar Kragujevac

Nikola Vojislav Rosić, Univerzitet u Kragujevcu, Medicinski fakultet

lekar, specijalista klinički farmakolog, Služba za kliničku farmakologiju, Klinički centar Kragujevac

Slobodan Mirko Simović, Univerzitet u Kragujevcu, Medicinski fakultet

lekar, Dispanzer za opštu medicinu, Dom zdravlja "Miloje Hadžić-Šule" Rača Kragujevačka

Reference

Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009;65:414–26.

Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clinical infectious diseases 2008;46(8):1254-63.

Jang TN, Lee SH, Huang CH, Lee CL, Chen WY. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. J Hosp Infect 2009;73(2):143-50.

Mahgoub S, Ahmed J, Glatt AE. Underlying characteristics of patients harboring highly resistant Acinetobacter baumannii. Am J Infect Control 2002;30(7):386-90.

Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21(3):538-82.

Falagas ME, Rafailidis PI. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit Care 2007;11(3):134.

Falagas M, Bliziotis I, Siempos I. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006;10(2):48.

Ecker JA, Massire C, Hall TA, Ranken R, Pennella TD, Agasino IC, Pe M. Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry. J Clin Microbiol 2006;44(8):2921-32.

Mioljević V, Simić A, Radenković D et al. Acinetobacter spp. colonization and infection risk factors in surgical patients. Acta Chir Iugosl. 2011;58(4):81-7.

Mioljević V, Jovanović B, Mazić N, Palibrk I, Milićević M. Rezultati epidemiološkog nadzora nad bolničkim infekcijama na Klinici za digestivnu hirurgiju KCS u 2007. godini. Acta Chir Iugosl 2009;56(2):47-51.

Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clinical infectious diseases 2005;40(9):1333-41.

Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of gram-negative and gram-positive organisms: tigecycline evaluation and surveillance trial 2004 to 2007. Diagn Microbiol Infect Dis 2009;65(3):288-99.

Poulakou G, Kontopidou FV, Paramythiotou E, Kompoti M, Katsiari M, Mainas E, Clouva P. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect 2009;58(4):273-84.

Bishburg E, Bishburg K. Minocycline: an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents 2009;34(5):395-401.

Sinha M, Srinivasa H, Macaden R. Antibiotic resistance profile & extended spectrum beta-lactamase (ESBL) production in Acinetobacter species. Indian J Med Res 2007;126(1):63-7.

Lee K, Lee WG, Uh Y, Ha GY, Cho J, Chong Y. VIM- and IMP-type metallo-beta-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerging Infect Dis 2003;9(7):868-71.

Akers KS, Chaney C, Barsoumian A, Beckius M, Zera W, Yu X, Murray CK. Aminoglycoside resistance and susceptibility testing errors in Acinetobacter baumannii-calcoaceticus complex. J Clin Microbiol 2010;48(4):1132-8.

Gounden R, Bamford C, Van ZR, Cohen K, Maartens G. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infectious Diseases 2009;9(1):26.

Fass RJ, Barnishan J, Solomon MC, Ayers LW. In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrob Agents Chemother 1996;40(6):1412-8.

Corbella X, Pujol M, Ayats J, Sendra M, Ardanuy C, Dominguez MA, Gudiol F. Relevance of Digestive Tract Colonization in the Epidemiology of Nosocomial Infections Due to Multiresistant Acinetobacter baumannii. Clin Infect Dis 1996;23(2):329-34.

Lortholary O, Fagon JY, Hoi AB, Slama MA, Pierre J, Giral P, Acar J. Nosocomial Acquisition of Multiresistant Acinetobacter baumannii: Risk Factors and Prognosis. Clin Infect Dis 1995;20(4):790-6.